ENTA has 36-month beta value of 0.60. Analysts have mixed views on the stock, with 3 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for ENTA is 19.65M, and currently, short sellers hold a 13.97% ratio of that float. The average trading volume of ENTA on May 08, 2024 was 224.30K shares.
ENTA) stock’s latest price update
Enanta Pharmaceuticals Inc (NASDAQ: ENTA)’s stock price has dropped by -10.27 in relation to previous closing price of 14.60. Nevertheless, the company has seen a loss of -4.66% in its stock price over the last five trading days. Seeking Alpha reported 2024-05-06 that Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA ) Q2 2024 Earnings Conference Call May 6, 2024 4:30 PM ET Company Participants Jennifer Viera – Investor Relations Jay Luly – President and Chief Executive Officer Paul Mellett – Chief Financial Officer Scott Rottinghaus – Chief Medical Officer Tara Kieffer – Chief Product Strategy Officer Conference Call Participants Eric Joseph – JPMorgan Roy Buchanan – Citizens JMP Nik Gasic – Leerink Partners Jay Olson – Oppenheimer Operator Good afternoon and welcome to Enanta Pharmaceuticals’ Fiscal Second Quarter Financial Results Conference Call. At this time, all participants are on a listen-only mode.
ENTA’s Market Performance
ENTA’s stock has fallen by -4.66% in the past week, with a monthly drop of -19.93% and a quarterly rise of 4.47%. The volatility ratio for the week is 8.00% while the volatility levels for the last 30 days are 5.83% for Enanta Pharmaceuticals Inc The simple moving average for the past 20 days is -8.78% for ENTA’s stock, with a 3.17% simple moving average for the past 200 days.
Analysts’ Opinion of ENTA
Many brokerage firms have already submitted their reports for ENTA stocks, with JP Morgan repeating the rating for ENTA by listing it as a “Underweight.” The predicted price for ENTA in the upcoming period, according to JP Morgan is $14 based on the research report published on August 09, 2023 of the previous year 2023.
Jefferies, on the other hand, stated in their research note that they expect to see ENTA reach a price target of $18, previously predicting the price at $49. The rating they have provided for ENTA stocks is “Hold” according to the report published on August 08th, 2023.
H.C. Wainwright gave a rating of “Buy” to ENTA, setting the target price at $56 in the report published on December 09th of the previous year.
ENTA Trading at -11.87% from the 50-Day Moving Average
After a stumble in the market that brought ENTA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -63.65% of loss for the given period.
Volatility was left at 5.83%, however, over the last 30 days, the volatility rate increased by 8.00%, as shares sank -22.12% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -6.70% lower at present.
During the last 5 trading sessions, ENTA fell by -4.66%, which changed the moving average for the period of 200-days by -30.32% in comparison to the 20-day moving average, which settled at $14.17. In addition, Enanta Pharmaceuticals Inc saw 39.21% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ENTA starting from Vance Terry, who sale 15,295 shares at the price of $9.12 back on Dec 13 ’23. After this action, Vance Terry now owns 5,800 shares of Enanta Pharmaceuticals Inc, valued at $139,490 using the latest closing price.
Luly Jay R., the President and CEO of Enanta Pharmaceuticals Inc, sale 7,230 shares at $9.63 during a trade that took place back on Dec 05 ’23, which means that Luly Jay R. is holding 806,793 shares at $69,625 based on the most recent closing price.
Stock Fundamentals for ENTA
Current profitability levels for the company are sitting at:
- -1.93 for the present operating margin
- 0.97 for the gross margin
The net margin for Enanta Pharmaceuticals Inc stands at -1.88. The total capital return value is set at -0.39. Equity return is now at value -60.50, with -35.60 for asset returns.
Based on Enanta Pharmaceuticals Inc (ENTA), the company’s capital structure generated 0.12 points at debt to capital in total, while cash flow to debt ratio is standing at -3.63. The debt to equity ratio resting at 0.13. The interest coverage ratio of the stock is -64.06.
Currently, EBITDA for the company is -123.48 million with net debt to EBITDA at 0.11. When we switch over and look at the enterprise to sales, we see a ratio of 3.57. The receivables turnover for the company is 1.84for trailing twelve months and the total asset turnover is 0.17. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.43.
Conclusion
To put it simply, Enanta Pharmaceuticals Inc (ENTA) has had a mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
